$STE · STERIS plc
STERIS reported fiscal Q2 2027 (ended September 30, 2026) results: revenue up 9% to $1.589B, GAAP diluted EPS $2.19, adjusted diluted EPS $2.94 (vs $2.47 a year ago). Constant currency organic revenue growth was 8%. The company raised FY2027 adjusted EPS guidance to $11.35–$11.55 from $11.10–$11.30, including ~$0.18 from tariff refunds received year-to-date.
- Revenue rose 9% to $1.589B; constant currency organic growth was 8%.
- Adjusted diluted EPS was $2.94, up from $2.47 a year ago.
- Life Sciences revenue grew 18% to $170.6M, driving a raised segment outlook to 9-10% growth.
- FY2027 adjusted EPS guidance raised to $11.35–$11.55 from $11.10–$11.30.
- Six-month free cash flow was $492.5M, down from $527.7M a year ago.
Extended-hours last trade $260.86, up 5.22% vs the $247.91 regular close, reflecting a positive reaction to the beat and raised guidance.
STERIS beat on adjusted EPS and raised full-year guidance, with Life Sciences momentum and tariff refunds adding upside.
STERIS's Life Sciences strength and tariff-refund benefit contrast with peers facing tariff cost pressure in the medtech supply chain.
A new $45M restructuring plan (Healthcare segment) was approved, with ~$25M of charges in Q2 and only ~$9M in annualized savings expected.